Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 11,142.7% in August

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 616,887 shares, an increase of 11,142.7% from the August 15th total of 5,487 shares. Currently, 5.5% of the company’s shares are short sold. Based on an average daily trading volume, of 893,115 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analyst Weigh In

APRE has been the topic of several recent analyst reports. Wedbush reduced their price objective on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.07.

Aprea Therapeutics Trading Down 0.3%

APRE traded down $0.00 during midday trading on Thursday, hitting $0.79. The company’s stock had a trading volume of 61,302 shares, compared to its average volume of 967,729. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.69. The firm has a 50-day moving average price of $0.72 and a two-hundred day moving average price of $0.78. The firm has a market cap of $9.94 million, a P/E ratio of -0.73 and a beta of 1.54.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 47.60%. On average, equities analysts expect that Aprea Therapeutics will post -0.34 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A number of hedge funds have recently made changes to their positions in APRE. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics during the 4th quarter worth $40,000. DRW Securities LLC acquired a new position in Aprea Therapeutics in the fourth quarter valued at $103,000. Finally, AIGH Capital Management LLC grew its position in Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after acquiring an additional 645,000 shares during the period. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.